# US 2010/0168168 A1 · Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168168 A1
- Document ID: US20100168168A1
- Status: Published application
- Kind: A1
- Application number: 11/990,383
- Filed: 2005-10-26
- Published: 2010-07-01
- Earliest claimed: 2005-08-12
- Assignees: Suven Life Sciences Limited
- Inventors: Venkata Satya Nirogi Ramakrishna; Vikas Shreekrishna Shirsath; Rama Sastri Kambhampati; Santosh Vishwakarma; Nagaraj Vishwottam Kandikere; Srinivasulu Kota; Venkateswarlu Jasti
- Web page: https://patentgrep.com/patent/US20100168168A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT6 receptor. Pharmacological profiles of these components include high affinity binding with 5-HT6 receptors along with good selectivity towards the receptor. The present invention also includes stereoisomers, the salts, methods of preparation and medicine containing the aminoaryl sulphonamide derivatives.

## Claims

### Claim 1

A compound having the Formula (I),
or a pharmaceutically acceptable salt thereof wherein:
—Ar represents any one group selected from phenyl, naphthyl, a monocyclic or bicyclic heteroaryl, each of which may be further substituted by one or more independent substituents and those substituents are defined as R1;
R represents either a hydrogen atom, (C1-C3)alkyl or halo(C1-C3)alkyl group;
R1 and R4 independently represents one or multiple substitutions on the benzene ring, and includes a hydrogen, halogen, cyano, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkoxy, cyclo(C3-C6)alkyl or cyclo(C3-C6)alkoxy;
R2 whenever present, represents hydrogen, halogen, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkoxy,
R3 whenever present, represents hydrogen, (C1-C3)alkyl or halo(C1-C3)alkyl;
R5 and R6 represents either hydrogen or methyl.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein Ar is phenyl, naphthyl, indolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl or benzimidazolyl.

### Claim 3 (depends on 1)

A compound as claimed in claim 1 wherein R is a hydrogen atom, methyl or ethyl.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein R1 and R4 is a hydrogen, halogen, perhaloalkyl, perhaloalkoxy, cyano, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkoxy, alkoxy(C1-C3)alkoxy, hydroxy(C1-C3)alkoxy, cyclo(C3-C6)alkyl or cyclo(C3-C6)alkoxy.

### Claim 5 (depends on 1)

A compound as claimed in claim 1 wherein R2, represents hydrogen, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkoxy.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 wherein R3 represents hydrogen, (C1-C3)alkyl or halo(C1-C3)alkyl.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 wherein R5 and R6 represents hydrogen.

### Claim 8 (depends on 1)

A compound as claimed in claim 1 selected from among the following group:
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-1H-indole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-5-methoxyindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-5-isopropoxyindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-5-Bromoindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-5-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-5-fluoroindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-4-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-6-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonylindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-5-methoxyindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-5-isopropoxyindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-5-bromoindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-5-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-5-fluoroindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-4-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methyl]benzenesulfonyl-6-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methoxy]benzenesulfonyl-1H-indole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-5-methoxyindole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-5-isopropoxyindole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-5-bromoindole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-5-chloroindole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-5-fluoroindole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-4-chloroindole;
1-[(3-(1-Methylpiperidin-4-yl)amino)-4-methoxy]benzenesulfonyl-6-chloroindole;
1-[3-(1-Methylpiperidin-4-yl)amino-4-Fluoro]benzenesulfonylindole;
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-3-bromoindole.
1-[3-(1-Methylpiperidin-4-yl)amino-4-methoxy]benzenesulfonyl-3-bromoindole.
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-3-bromo-5-fluoroindole.
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-3-bromo-4-chloroindole.
1-[3-(1-Methylpiperidin-4-yl)methylamino]benzenesulfonylindole.
1-[3-(1-Methylpiperidin-4-yl)methylamino]benzenesulfony-5-methoxy-indole.
1-[3-(1-Methylpiperidin-4-yl)methylamino]benzenesulfony-5-fluoroindole.
1-[3-(1-Methylpiperidin-4-yl)acetamido]benzenesulfony-5-fluoroindole.
1-[3-(1-Methylpiperidin-4-yl)acetamido]benzenesulfonyindole.
1-[3-(1-Methylpiperidin-4-yl)ethylamino]benzenesulfony-5-fluoroindole.
1-[3-(1-Methylpiperidin-4-yl)amino]benzenesulfonyl-5-fluoroindole Hydrochloride salt;
1-[3-(1-Methylpiperidin-4-yl)amino-4-methoxy]benzenesulfonyl-1H-indole Hydrochloride salt; and a stereoisomer thereof; and a salt thereof.

### Claim 9

A process for the preparation of a compound of formula (I)
or a pharmaceutically acceptable salt thereof wherein:
—Ar represents any one group selected from phenyl, naphthyl, a monocyclic or bicyclic heteroaryl, each of which may be further substituted by one or more independent substituents and those substituents are defined as R1;
R represents either a hydrogen atom, (C1-C3)alkyl or halo(C1-C3)alkyl group;
R1 and R4 independently represents one or multiple substitutions on the benzene ring, and includes a hydrogen, halogen, cyano, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkoxy, cyclo(C3-C6)alkyl or cyclo(C3-C6)alkoxy;
R2 whenever present, represents hydrogen, halogen, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkoxy;
R3 whenever present, represents hydrogen, (C1-C3)alkyl or halo(C1-C3)alkyl;
R5 and R6 represents either hydrogen or methyl
which comprises of contacting a compound of formula (a) wherein R1, R4 and Ar are as defined in claim-1 earlier, with a piperidone derivative of formula (b):
wherein, R5, R6 and R are as defined above by reductive amination using a suitable reducing agent/catalyst in presence of inert solvent at ambient temperature to obtain a compound of formula (I).

### Claim 10

A process for the preparation of a compound of formula (I)
or a pharmaceutically acceptable salt thereof wherein:
—Ar represents any one group selected from phenyl, naphthyl, a monocyclic or bicyclic heteroaryl, each of which may be further substituted by one or more independent substituents and those substituents are defined as R1;
R represents either a hydrogen atom, (C1-C3)alkyl or halo(C1-C3)alkyl group;
R1 and R4 independently represents one or multiple substitutions on the benzene ring, and includes a hydrogen, halogen, cyano, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy; halo(C1-C3)alkoxy, cyclo(C3-C6)alkyl or cyclo(C3-C6)alkoxy;
R2 whenever present, represents hydrogen, halogen, (C1-C3)alkyl, halo(C1-C3)alkyl, (C1-C3)alkoxy or halo(C1-C3)alkoxy;
R3 whenever present, represents hydrogen, (C1-C3)alkyl or halo(C1-C3)alkyl;
R5 and R6 represents either hydrogen or methyl
which comprises of carrying out nucleophilic substitution in a compound of formula (a) herein, R1, R4 and Ar are as defined in claim-1 earlier, with a piperidinyl halide of formula (c):
wherein R5, R6 and R are as defined above; X represents as a halogen atom such as fluoro, chloro or iodo, using a suitable base and inert solvent at a suitable temperature.

### Claim 11 (depends on 9, 10)

A process as claimed in claim 9 or 10, optionally including
a. converting a compound of the formula (I) into another compound of the formula (I)
b. removing any protecting groups; or
c. forming a pharmaceutically acceptable salt, solvate or a prodrug thereof.

### Claim 12

A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula (I) as defined in any one of claim-1 to claim-8.

### Claim 13 (depends on 12)

A method as claimed in claim 12 wherein said disorder is an anxiety disorder, a cognitive disorder, or a neurodegenerative disorder.

### Claim 14 (depends on 12)

A method as claimed in claim 12 wherein said disorder is Alzheimer's disease or Parkinson's disease.

### Claim 15 (depends on 12)

A method as claimed in claim 12 wherein said disorder is attention deficit disorder or obsessive compulsive disorder.

### Claim 16 (depends on 12)

A method as claimed claim 12 wherein said disorder is stroke or head trauma.

### Claim 17 (depends on 12)

The method as claimed in claim 12 wherein said disorder is eating disorder or obesity.

### Claim 18

A pharmaceutical composition, which comprises a pharmaceutically acceptable carrier and, an effective amount of a compound of formula (I) as defined in any one of claim-1 to claim-8.

### Claim 19 (depends on 1, 8)

A compound of formula (I) as defined in any one of claim 1 to claim 8 for use as a medicament.
